Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016 ; volume:22 ; number:1 ; day:4 ; month:6 ; year:2022 ; pages:1-11 ; date:12.2022
BMC health services research ; 22, Heft 1 (4.6.2022), 1-11, 12.2022
- Urheber
-
Spanggaard, M.
Olsen, J.
Jensen, K. F.
Anderson, M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-022-08143-7
- URN
-
urn:nbn:de:101:1-2022080320314736274358
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Spanggaard, M.
- Olsen, J.
- Jensen, K. F.
- Anderson, M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer